Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO® / JESPECT®, indicated for the prevention of Japanese encephalitis, and DUKORAL®, indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by enterotoxigenic E. coli.

The company has various vaccines in development including a unique vaccine against Lyme disease.

Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada, and the US with over 450 employees.